Lupin is debuting three new generic products.
The first product is lapatinib tablets, which comes in a dosage strength of 250 mg.
Lapatinib tablets are the generic equivalent of Novaretis’ Tykerb.
The medication is indicated in combination with: Capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2, or HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab; and Letrozole for the treatment of postmenopausal women with hormone-receptor positive metastatic breast cancer that overexpresses the HER2 receptor, for whom hormonal therapy is indicated.
Lapatinib tablets had a market value of approximately $61 million, according to IQVIA June 2020 data.
Lupin’s second new entry is fosaprepitant for injection, 150 mg single-dose vial.
It is the generic of Merck Sharp & Dohme’s Emend.
The medication is indicated for adults in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin; and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
Fosaprepitant for injection had a market value of roughly $136 million, according to IQVIA July 2020 data.
Lupin’s also is introducing atorvastatin calcium tablets.
The product, which is available in dosage strengths of 10 mg, 20 mg, 40 mg, and 80 mg, is the generic of Pfizer’s Lipitor. It is indicated to lower cholesterol in blood for adults and children over 10 years of age; and to lower the risk of heart attack and stroke in patients with cardiovascular diseases, diabetes and other risk factors such as eye problems, kidney diseases or high blood pressure.
Atorvastatin calcium tablets had a market value of approximately $559 million, according to IQVIA July 2020 data.